Imanishi Yasuo, Taniuchi Satsuki, Kodama Sho, Yoshida Hisako, Ito Tetsuo, Kawai Ryota, Okubo Naoki, Shintani Ayumi
Department of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-Ku, Osaka, 545-8585, Japan.
Department of Medical Statistics, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-Ku, Osaka, 545-8585, Japan.
Clin Exp Nephrol. 2025 Feb;29(2):236-247. doi: 10.1007/s10157-024-02562-y. Epub 2024 Oct 14.
Few studies have investigated fracture risk and mortality in a Japanese chronic kidney disease (CKD) stages G3-5 population using a large-scale clinical database.
This retrospective cohort study extracted data from 1 April 2008 to 30 April 2023. A single age-sex-matched control without CKD was matched with each non-dialysis CKD (estimated glomerular filtration rate < 60 mL/min/1.73 m) patient. The incidences of all and hip fractures and all-cause mortality after the index date were calculated.
Among 76,598 (38,299 per group) individuals matched, the incidence of all fractures did not differ between the CKD and control groups (5.7% vs 5.8%; hazard ratio [HR] 1.022 [95% confidence interval CI 0.952-1.098], P = 0.542). The CKD group had higher risk of hip fracture than the control group (incidence of hip fracture, 1.7% vs 1.3%; HR 1.415 [95% CI 1.234-1.622], P < 0.001). Multivariable regression analysis showed an increased risk for hip fracture in the CKD vs control groups, and a greater difference in this risk was observed with younger age. Osteoporosis treatment and bone mineral density (BMD) measurements were 10.0% and 5.3% in the CKD group and 4.4% and 4.4% in the control group, respectively. Mortality was also higher in the CKD group (HR 1.413 [95% CI 1.330-1.501], P < 0.001).
Japanese patients with CKD had higher risk of hip fracture than those without. Treatment and BMD measurement for fracture are insufficient in Japanese patients with CKD, and more adequate management of fracture risk is needed.
很少有研究使用大规模临床数据库调查日本慢性肾脏病(CKD)G3 - 5期人群的骨折风险和死亡率。
这项回顾性队列研究提取了2008年4月1日至2023年4月30日的数据。为每位非透析CKD(估计肾小球滤过率<60 mL/min/1.73 m²)患者匹配一名无CKD的年龄和性别匹配的对照。计算索引日期后的所有骨折和髋部骨折的发生率以及全因死亡率。
在76598名(每组38299名)匹配个体中,CKD组和对照组的所有骨折发生率无差异(5.7%对5.8%;风险比[HR] 1.022 [95%置信区间CI 0.952 - 1.098],P = 0.542)。CKD组髋部骨折风险高于对照组(髋部骨折发生率,1.7%对1.3%;HR 1.415 [95% CI 1.234 - 1.622],P < 0.001)。多变量回归分析显示,CKD组与对照组相比髋部骨折风险增加,且在年轻患者中这种风险差异更大。CKD组的骨质疏松治疗和骨密度(BMD)测量分别为10.0%和5.3%,对照组分别为4.4%和4.4%。CKD组的死亡率也更高(HR 1.413 [95% CI 1.330 - 1.501],P < 0.001)。
日本CKD患者的髋部骨折风险高于非CKD患者。日本CKD患者的骨折治疗和BMD测量不足,需要更充分地管理骨折风险。